🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

13 recruiting trials

for ALL, Childhood B-Cell

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies NCT06508775NA7 sites📍 Berlin📍 Cologne📍 Erlangen Miltenyi Biomedicine GmbH · Tests: MB-CART19.1, MB-CART20.1, MB-CART2019.1 Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide Newly-diagnosed Pediatric Ph-positive B-ALL Protocol NCT07152041Phase 324 sites📍 Hefei📍 Chongqing📍 Fuzhou Institute of Hematology & Blood Diseases Hospital, China · Tests: olverembatinib A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab NCT07422337n/a2 sites📍 Little Rock📍 Springdale Arkansas Children's Hospital Research Institute Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia NCT05366218Phase 1, Phase 211 sites📍 Freiburg im Breisgau📍 Tübingen📍 Ulm University Hospital Tuebingen · Tests: Tafasitamab Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT NCT04746209Phase 21 site📍 Milwaukee Medical College of Wisconsin · Tests: Alpha/Beta T-cell and B-cell depleted HCT, Blinatumomab International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) NCT07476729Phase 321 sites📍 Vienna📍 Ghent📍 Prague Charite University, Berlin, Germany · Tests: Inotuzumab ozogamicin (INO), Blinatumomab Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol NCT06764238Phase 2, Phase 327 sites📍 Hefei📍 Hefei📍 Fuzhou Institute of Hematology & Blood Diseases Hospital, China · Tests: Blinatumomab (Group A), Venetoclax (nonRand Group), Blinatumomab (Group B) Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol NCT06882057Phase 2, Phase 327 sites📍 Hefei📍 Hefei📍 Chongqing Institute of Hematology & Blood Diseases Hospital, China · Tests: Blinatumomab, Reinduction-2 omission, Chemo-light Maintenance 2 A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL NCT05748171Phase 265 sites📍 Vienna📍 Brussels📍 Ghent Pfizer · Tests: Inotuzumab ozogamicin, ALLR3 Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL) NCT07078929Phase 13 sites📍 Bangkok📍 Chiang Mai📍 Bangkok Chulalongkorn University · Tests: CD19-IL7Ra CAR-T cells CAR-T Cell Therapy for ALL NCT07695012EARLY Phase 11 site📍 Rawalpindi Dr. Zaineb Akram · Tests: CAR-T cell infusion Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies NCT05418088Phase 12 sites📍 Columbus📍 Columbus Sumithira Vasu · Tests: Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate, Echocardiography, Multigated Acquisition Scan
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy